The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with menopause as well as a common breast cancer therapy.

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the use case for the menopause treatment expected to launch as early as this ...

Whether ahead of their time, truly bizarre, or just plain doomed, it’s certainly interesting to see companies go completely off-script. (The Zappos experiment with “Holocracy” memorably comes to mind.

Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...

Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...

Bayer AG reported positive results for elinzanetant ... The German company’s drug met all the goals of a late-stage study for the treatment of moderate to severe vasomotor symptoms, also known ...